NEW YORK, Dec. 29, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Evaluate the status, opportunities and threats for pharmaceutical companies in Brazil, Russia, India and China now and in the future. Market forecasts to 2014 are provided, plus free quarterly-updated market outlook reports on each country, keeping you up to date with developments for a full year.
Many are concerned that a potential global economic downturn could blunt the rapid growth in the BRIC countries. Is this a time of exciting opportunity or commercial danger for pharmaceutical manufacturers? This report is essential in making sound, impartial business judgments.
These insightful reports provide:
Five-year forecasts to 2014 and market valuations for each market.
Quarterly updated reports of key market developments.
A detailed analysis of the health structure, funding, service and outlook.
Putting things in perspective
The BRIC pharmaceutical markets are currently valued at US$58.4 billion. This is a large sum of money, but is collectively lower than found in leading markets such as the USA and Japan. Growth rates vary but, overall, they are impressive.
Opportunities do exist
There are wide regional differences in expenditure levels within the BRIC markets, far more so than in developed countries where health systems have evolved to provide a more uniform level of coverage. All four countries have a relatively wealthy urban population with a far greater spending power than their respective national average. In the case of China and India, these urban populations have grown rapidly, and number hundreds of millions. The challenge for these countries is to extend this level of wealth to the rest of the population, in order that better levels of healthcare become affordable.
A long haul
This is evolution not revolution, and change will be incremental. Short-term opportunities exist in meeting the health demands of the burgeoning middle classes, and future prospects are bright, where steady growth in BRIC markets will erode commercial differences with the established markets in North America, Japan and Europe.
Current and accurate decision support information is vital
Effective planning is vital and that is why Espicom, the leading provider of pharmaceutical market intelligence, has issued this collection The Market for Pharmaceuticals in Brazil, Russia, India & China 2009. For each country there is a comprehensive examination of the pharmaceutical market which covers all aspects of the operating environment from the regulatory situation through health provision/expenditure to domestic production. Importantly, each market evaluation includes five-year growth forecasts and SWOT analysis. An additional benefit - at no extra cost – is that quarterly-updated outlook reports are included in the price.
HIGHLIGHTS FROM THE REPORTS...
Brazil is the second most attractive BRIC market for pharmaceutical producers. Controlled drug prices are growing at below inflational levels but price controls are not directly linked to consumption levels. In fact, between 1997 and 2008, the pharmaceutical market by volume increased significantly only in 2004. Demand should increase as the country is emerging from the economic downturn much quicker than anticipated, therefore the outlook is very positive compared to other Latin American markets. The exchange rate of the real against the US dollar fell in early 2009, but it has now recovered. This is good news for producers as imports are now cheaper; Brazil, in contrast with other BRIC countries such as India, still relies on raw material imports, which diminishes its market strength.
In population terms, Russia is a potentially vast market. Health spending is generally very low, however, in comparison with Western countries. Around 75% of the pharmaceutical market is supplied by imports. The domestic generic industry is sizeable, but the local production of innovative drugs is negligible. Russian manufacturers are small and under-funded, often making do with outdated equipment. The market environment remains challenging for overseas companies. Major problems reported in Russia include corruption, bureaucracy, counterfeiting and poor data confidentiality. Government officials and politicians often discriminate in favour of the domestic industry, and enforcement of existing rules is often weak.
India has a huge population in excess of one billion people and a growing middle class with access to high quality healthcare. Conversely, in this geographically vast country plagued by natural disasters, the majority of the population is both rural and poor and western style pharmaceuticals are not even an issue for millions of people. India has an established domestic industry, responsible for around 8% of world pharmaceutical production. The larger domestic companies are striving to compete in the global market for both generics and original products. The market is dominated by low priced, domestically-produced generics and relatively low per capita expenditure on pharmaceuticals.
China's pharmaceutical market looks set to grow even further in the short-term, with the establishment of an Essential Medicines System during the 2009-2011 period. The plan calls for an estimated 300-400 essential medicines to be made available at all public facilities, starting at the grassroots level. In October 2009, the NDRC reduced the prices of 2,349 drugs by an average 12%. These drugs represent around 45% of drugs on the Essential Medicines System. The prices of 49% of drugs on the list will not be reduced while the remaining 6% that are in short supply will see their prices increased moderately in order to encourage their manufacture.
DETAILED REPORT CONTENTS
Key National Indicators
Economic, population, and health data forecast to 2014
Organisation & administration
Expenditure by source of funding and type
Hospital data such as beds by type, region, specialty, patient admissions and surgical procedures
Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists
Accessing the pharmaceutical market
Distribution guide and trade fair information
For healthcare organisations and trade associations
QUARTERLY-UPDATED REPORTS INCLUDED!
Buyers of this report will receive, for each market, 4 quarterly reports covering:
Current market size
Unique 5-year market projections to 2014
Market outlook & structure
Comment & rating
Import and export data
Market developments, covering recent and impending developments with respect to key issues such as regulation, health facilities, and funding
To order this report:
Intl: +1 805-652-2626